| 13th Feb 2025 4:15 pm |
RNS |
PDMR Transaction Notification |
| 13th Feb 2025 7:00 am |
RNS |
Grant of Share Options |
| 5th Feb 2025 7:00 am |
RNS |
Unaudited full year trading update |
| 27th Jan 2025 7:00 am |
RNS |
Anders Lundstrom appointed CEO |
| 24th Dec 2024 11:25 am |
RNS |
Result of General Meeting & Total Voting Rights |
| 23rd Dec 2024 7:00 am |
RNS |
Results of RetailBook Offer |
| 6th Dec 2024 11:31 am |
RNS |
RetailBook Offer |
| 6th Dec 2024 11:30 am |
RNS |
Subscription by AOP Health to raise US$10 million |
| 21st Nov 2024 7:00 am |
RNS |
Business Update |
| 29th Oct 2024 7:00 am |
RNS |
Q3 Trading Update |
| 25th Sep 2024 7:00 am |
RNS |
Results from Phase 3 paediatric study |
| 4th Sep 2024 7:00 am |
RNS |
Interim results |
| 27th Aug 2024 7:00 am |
RNS |
ACCRUFeR® Approved by Health Canada |
| 14th Aug 2024 7:00 am |
RNS |
Notice of interim results |
| 24th Jul 2024 7:01 am |
RNS |
Unaudited Q2 2024 Trading Update |
| 24th Jul 2024 7:00 am |
RNS |
Directorate Change |
| 3rd Jul 2024 7:00 am |
RNS |
$5.7m Milestone Monetization Agreement with AOP |
| 20th Jun 2024 4:25 pm |
RNS |
Results of 2024 Annual General Meeting |
| 28th May 2024 7:00 am |
RNS |
New Drug Application for Accrufer® in South Korea |
| 23rd May 2024 7:15 am |
EQS |
Hardman & Co: Shield Therapeutics (STX): Cash management is key |
| 10th May 2024 3:30 pm |
RNS |
Audited results for the year ended 31 Dec 2023 |
| 30th Apr 2024 7:00 am |
RNS |
Business Update for Q1 2024 |
| 16th Apr 2024 7:00 am |
RNS |
Notice of Results |
| 21st Feb 2024 7:00 am |
RNS |
Unaudited Full Year Trading Update |
| 9th Jan 2024 7:00 am |
RNS |
Appointment of new Chief Financial Officer |
| 7th Dec 2023 7:00 am |
RNS |
Q3 2023 U.S. Commercial Highlights |
| 27th Nov 2023 5:24 pm |
RNS |
PDMR Transaction Notification |
| 15th Nov 2023 7:30 am |
EQS |
Hardman & Co Research on Shield Therapeutics (STX): Accelerating effectiveness of enlarged sales team |
| 20th Oct 2023 11:45 am |
RNS |
Abstract to be presented at Healthcare Conference |
| 12th Oct 2023 7:00 am |
RNS |
Chief Financial Officer Transition |
| 3rd Oct 2023 3:00 pm |
RNS |
Result of REX Retail Offer |
| 3rd Oct 2023 7:00 am |
RNS |
Block listing Interim Return |
| 3rd Oct 2023 7:00 am |
RNS |
Completion of SWK Financing |
| 28th Sep 2023 12:50 pm |
RNS |
Successful completion of US$6.1m Equity Fundraise |
| 28th Sep 2023 7:02 am |
RNS |
REX Retail Offer |
| 28th Sep 2023 7:01 am |
RNS |
$20m secured debt facility &proposed equity raise |
| 28th Sep 2023 7:00 am |
RNS |
Interim results update and business update |
| 6th Sep 2023 7:00 am |
RNS |
Notice of Results and Change in reporting currency |
| 25th Jul 2023 9:45 am |
EQS |
Hardman & Co Research on Shield Therapeutics (STX): Accrufer Rx momentum gathering |
| 24th Jul 2023 2:27 pm |
RNS |
Holding(s) in Company |
